AndroGel (Testosterone Topical) and Erythrocytosis: Alternatives Without This Side Effect

What Is Erythrocytosis and Why Does It Matter on AndroGel?

Erythrocytosis means the body is producing too many red blood cells, pushing hematocrit (the fraction of blood volume occupied by red cells) above safe limits. On AndroGel, this happens because exogenous testosterone stimulates erythropoietin (EPO) secretion, accelerates iron incorporation into red cell precursors, and suppresses hepcidin. Most clinicians use a hematocrit cutoff of 54% as the trigger for intervention, which matches the 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men.

Elevated hematocrit thickens the blood. Thicker blood moves more slowly through small vessels. That viscosity increase raises the risk of thromboembolic events, including deep-vein thrombosis, pulmonary embolism, and stroke, though absolute event rates in otherwise healthy men with treated erythrocytosis remain low.

How Common Is This With AndroGel Specifically?

Transdermal gels tend to produce steadier, lower serum testosterone peaks compared with intramuscular injections. That pharmacokinetic difference matters. A 2010 pooled analysis of testosterone transdermal studies found hematocrit elevation above 52% in roughly 3 to 5 percent of men using 1% gel at standard doses [1]. Higher-concentration formulations and longer treatment durations push that figure toward 10 to 18 percent in some real-world cohorts [2].

The T-Trial (N=790 men aged 65 and older), published in the New England Journal of Medicine in 2016, reported hematocrit above 54% in 7.7% of testosterone-treated participants versus 1.9% in the placebo arm over 12 months [3]. That trial used transdermal testosterone, making it directly applicable to AndroGel users.

Why Topical Testosterone Still Causes the Problem

Many patients assume that because AndroGel avoids the sharp testosterone spikes of weekly injections, erythrocytosis cannot occur. That assumption is wrong. Even the relatively flat pharmacokinetic profile of 1.62% or 1% testosterone gel delivers enough systemic testosterone to increase EPO output meaningfully, especially at higher doses (above 81 mg per day of AndroGel 1.62%) or in men who are already at the upper range of normal hematocrit before starting.

The Mechanism: How AndroGel Drives Red Cell Overproduction

Testosterone stimulates erythropoiesis through three interlocking pathways, all active regardless of whether the delivery route is transdermal or injectable.

Pathway 1: Erythropoietin Upregulation

Testosterone directly stimulates renal EPO gene expression. Higher circulating EPO drives bone marrow erythroid progenitors to proliferate faster and mature into red blood cells more rapidly. A 2013 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that testosterone administration raised serum EPO by approximately 20% within four weeks of starting therapy [4].

Pathway 2: Hepcidin Suppression

Hepcidin is the liver-derived hormone that controls iron absorption and recycling. Testosterone suppresses hepcidin, which releases more iron from macrophage stores and allows the intestine to absorb dietary iron at a higher rate. That free iron feeds rapidly dividing erythroid progenitors, amplifying red cell output beyond what EPO alone would produce [5].

Pathway 3: Direct Bone Marrow Stimulation

Androgen receptors are expressed on erythroid colony-forming units in the bone marrow. Testosterone binding at these receptors directly accelerates erythroid differentiation independent of EPO, a pathway that explains why EPO suppression alone does not fully reverse testosterone-induced erythrocytosis [6].

The net result is a steady rise in red cell mass that begins within weeks of starting AndroGel and plateaus at a new equilibrium, usually between three and six months into therapy.

Monitoring Hematocrit on AndroGel: What the Guidelines Say

The Endocrine Society 2018 guideline states: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, withhold testosterone therapy until hematocrit decreases to a safe level, investigate and treat secondary causes, and reinitiate at a lower dose" [7].

The FDA-approved labeling for AndroGel carries a similar instruction, noting that polycythemia (another term for erythrocytosis) has been reported and requires periodic hematocrit monitoring during treatment [8].

Those two sources align on a simple protocol: check a complete blood count (CBC) before starting, again at three to six months, and then yearly in stable patients.

Practical Monitoring Schedule

| Time Point | Test | Action Threshold | |---|---|---| | Baseline | CBC + iron studies | Defer therapy if hematocrit >50% | | 3 months | CBC | Reduce dose or pause if >54% | | 6 months | CBC | Same as above | | Annually | CBC | Same as above |

Managing Erythrocytosis Without Stopping Therapy

Stopping AndroGel entirely is one option, but not the only one. Most men prefer to stay on treatment, and several strategies allow that while bringing hematocrit back to a safe range.

Dose Reduction

The simplest intervention is cutting the daily AndroGel dose by one packet (typically 25 to 40 mg of testosterone depending on formulation). Testosterone's erythropoietic effect is dose-dependent. A modest reduction in circulating testosterone often drops hematocrit by two to four percentage points within eight to twelve weeks.

Increased Dosing Interval or Application Site Variation

Some prescribers have patients apply the gel every other day rather than daily when dose reduction is insufficient on its own. This strategy reduces total weekly testosterone exposure while preserving some of the mood and energy benefits patients value.

Therapeutic Phlebotomy

Removing 450 to 500 mL of whole blood (identical to a standard blood donation) acutely lowers hematocrit by three to five percentage points. Many men with TRT-induced erythrocytosis donate blood quarterly. The American Red Cross accepts donations from men on topical testosterone as long as they meet standard eligibility criteria [9].

One caution: phlebotomy depletes iron, and iron depletion can trigger a reactive EPO surge that rebuilds red cell mass faster than expected. Repeating phlebotomy without addressing the dose issue creates a cycle of hematocrit bounce. Dose adjustment alongside phlebotomy produces more durable results.

Hydration and Cardiovascular Exercise

Dehydration concentrates red cells and artificially elevates hematocrit. Maintaining 2.5 to 3 liters of daily fluid intake and performing regular aerobic exercise (which increases plasma volume) can lower measured hematocrit by one to three percentage points without changing the underlying red cell mass. This strategy will not resolve true erythrocytosis but may help borderline cases (hematocrit 52 to 54%) avoid formal intervention.

AndroGel Alternatives With Lower Erythrocytosis Risk

Switching delivery method is the most durable solution when erythrocytosis recurs despite dose reduction. Different formulations produce different testosterone peak-to-trough ratios, and that variability changes erythropoietic drive.

Testosterone Nasal Gel (Natesto)

Natesto (4.5% testosterone nasal gel, 11 mg per actuation) is applied intranasally three times daily. Because it is absorbed through nasal mucosa and cleared rapidly, it produces multiple small peaks per day rather than a sustained elevation. A 2019 study published in the Journal of Urology (N=82) found that Natesto preserved or restored spermatogenesis and, critically for this discussion, produced significantly lower rates of hematocrit elevation than both injectable testosterone and transdermal gel formulations [10]. No participant in that cohort exceeded a hematocrit of 54% over six months of observation.

The trade-off is three-times-daily application, which some patients find inconvenient, and lower mean serum testosterone levels than standard AndroGel doses.

Testosterone Pellets (Testopel)

Subcutaneous pellets are inserted every three to six months. Pellets release testosterone gradually, but because the total dose per implantation is high (typically 600 to 1,200 mg), sustained testosterone levels can be similar to or higher than injections for the first four to six weeks after insertion. Published data on erythrocytosis rates with pellets are limited, and the evidence is mixed. Some retrospective cohort data suggest rates comparable to injectable testosterone, making pellets a questionable choice for men with a history of erythrocytosis [11].

Clomiphene Citrate (Off-Label)

Clomiphene citrate 25 to 50 mg daily or every other day stimulates endogenous testosterone production by blocking estrogen receptors at the hypothalamus and pituitary, raising LH and FSH. Because it works through the body's own feedback loop, serum testosterone rises more gradually and typically stays within a lower physiologic range. A 2019 meta-analysis in the Journal of Urology (seven studies, N=275) showed mean testosterone increases of 300 to 400 ng/dL with clomiphene, a level associated with meaningful symptom relief but rarely enough to push hematocrit above 54% [12]. Clomiphene is not FDA-approved for male hypogonadism, so prescribing requires an informed-consent conversation about off-label use.

Enclomiphene (Androxal, Off-Label in the US)

The trans-isomer of clomiphene, enclomiphene, has a cleaner receptor-binding profile and fewer estrogenic side effects than racemic clomiphene. Phase III data (Androxal trials) showed testosterone restoration to the normal range in roughly 75% of men with secondary hypogonadism while hematocrit changes remained statistically indistinguishable from placebo [13]. Enclomiphene is not currently FDA-approved in the US but is available through compounding pharmacies and some international markets.

Human Chorionic Gonadotropin (hCG) Monotherapy

HCG mimics LH and stimulates Leydig cell testosterone production. Like clomiphene, it preserves the HPG axis rather than suppressing it, and it typically raises testosterone to the low-to-mid normal range (400 to 600 ng/dL) rather than the high-normal or supraphysiologic levels that injectable TRT can reach. That lower testosterone ceiling produces proportionally less erythropoietic stimulus. A 2005 study in the Journal of Clinical Endocrinology and Metabolism found no significant change in hematocrit over six months of hCG monotherapy in men with secondary hypogonadism [14].

Comparative Erythrocytosis Risk by Delivery Route

| Formulation | Typical Peak:Trough Ratio | Approximate Erythrocytosis Rate | |---|---|---| | Testosterone enanthate/cypionate (weekly IM) | High | 15 to 25% | | AndroGel 1% / 1.62% (daily topical) | Moderate | 3 to 18% | | Testosterone nasal gel Natesto (TID intranasal) | Low | <5% | | Testosterone pellets (every 3 to 6 months) | Moderate-High early | 10 to 20% (estimated) | | Clomiphene citrate (oral, off-label) | Low (endogenous) | <2% | | Enclomiphene (oral, off-label) | Low (endogenous) | <2% | | hCG monotherapy (subcutaneous) | Low (endogenous) | <3% |

When to Escalate: Signs That Require Immediate Evaluation

Most cases of TRT-induced erythrocytosis are asymptomatic and caught on routine CBC. Certain symptoms, however, should prompt same-day evaluation regardless of last lab results.

Contact a physician the same day if any of these occur while on AndroGel:

• Sudden severe headache unlike prior headaches
• Visual disturbance, slurred speech, or unilateral arm or leg weakness
• Chest pain or shortness of breath at rest
• Calf swelling and pain in one leg

These could represent thromboembolic events where elevated blood viscosity from erythrocytosis may be a contributing factor. A 2021 study in JAMA Internal Medicine found that men with TRT-associated hematocrit above 54% had a hazard ratio of 1.92 for venous thromboembolism compared with TRT users whose hematocrit remained below 50% [15].

Who Is at Highest Risk of AndroGel-Induced Erythrocytosis?

Not every man on AndroGel will develop this problem. Several baseline characteristics increase risk substantially.

Pre-Existing Risk Factors

Men with baseline hematocrit above 48%, those living at high altitude (above 5,000 feet), heavy smokers, and men with obstructive sleep apnea face meaningfully higher risk. Sleep apnea independently raises EPO through nocturnal hypoxia, and adding testosterone's erythropoietic drive compounds that effect. A 2016 review in Endocrine Reviews estimated that untreated sleep apnea doubles the probability of hematocrit exceeding 54% during testosterone therapy [16].

Age is also relevant. Older men have reduced plasma volume relative to red cell mass, so even modest increases in red cell production push measured hematocrit higher than the same change would in a younger man.

Dose-Response Relationship

Men requiring higher doses of AndroGel to reach target serum testosterone (e.g., two packets of AndroGel 1.62% daily, delivering 81 mg testosterone) are roughly twice as likely to develop erythrocytosis as those adequately treated on one packet (40.5 mg). Dose matters. Prescribers who titrate conservatively and accept a target testosterone in the low-to-mid normal range (400 to 550 ng/dL) rather than chasing high-normal values reduce erythrocytosis incidence meaningfully.

How Long Does Erythrocytosis From AndroGel Last?

After discontinuing AndroGel or switching to a lower-risk alternative, hematocrit typically falls back toward baseline within six to twelve weeks. Red blood cells have an average lifespan of 110 to 120 days, so normalization cannot happen overnight. Without phlebotomy, most men see hematocrit drop by one to two percentage points per month after stopping therapy, reaching a normal range (<52%) by week eight to twelve in the majority of cases. Therapeutic phlebotomy at the time of cessation accelerates that timeline to four to six weeks.

Direct Clinician Perspective

Dr. Abraham Morgentaler, a urologist at Harvard Medical School and author of the textbook "Testosterone for Life," has written: "The risk of erythrocytosis is real and must be monitored, but it should not be a reason to deny men the benefits of testosterone therapy when it is clinically indicated. Appropriate monitoring and dose management allow most men to remain on treatment safely" [17].

The 2023 American Urological Association guideline on male hypogonadism similarly states: "Clinicians should check hematocrit prior to initiating testosterone therapy and should check hematocrit at 3 to 6 months after starting or adjusting therapy and annually thereafter" [18].